We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Genesis Healthcare (GEN) This Season?
Read MoreHide Full Article
Genesis Healthcare, Inc. (GEN - Free Report) is scheduled to report second-quarter 2019 results on Aug 8.
The Zacks Consensus Estimate is pegged at a loss of 13 cents, which indicates 23.53% improvement from the year-ago reported figure. The consensus mark for revenues stands at $1.15 billion, implying a decline of 9.77% from the year-ago quarter’s reported figure.
Factors to Affect Q2 Results
We expect strong same-store EBITDAR growth driven by a more stable census and reimbursement environment, effective cost management, improvement in the company’s therapy and staffing businesses, and the impact of continued streamlining of its portfolio.
The company’s revenue growth will to some extent be offset by loss of revenues from divestitures, lower revenues in its rehab services business segments following the cancellation of low-margin therapy contracts.
The company’s expenses are likely to reduce due to decline in lease rental payments related to divestitures and closures. From 2018 through the first half of 2019, it made 65 divestitures. In the second quarter as well, it sold off 10 of its facilities.
As a result of improving operating trends and business portfolio optimization strategy, the company witnessed an increase in same-store occupancy levels in the first quarter and expects the same in the to-be-reported quarter.
We expect the company to deleverage its balance sheet with the funds received from numerous business sales made recently.
The company’s EBIDTA margins should also improve due to its focus on streamlining operations. In the last quarter, these reported margins were at their highest in two years, and the same should continue to improve in the coming quarters.
Earnings Surprise History
The company surpassed earnings estimates in three of the four reported quarters but the average remains a negative earnings surprise of 19.30%. This is depicted in the chart below:
Our proven model does not conclusively show that Genesis Healthcare is likely to beat earnings estimates this season because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to do so. But that is not the case here.
Earnings ESP: Genesis Healthcare has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter
Zacks Rank: Genesis Healthcare carries a Zacks Rank #3, which combined with Earnings ESP of 0.00% leaves our surprise prediction inconclusive.
Stocks That Warrant a Look
Here are some companies that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
TOL Brothers, Inc. (TOL - Free Report) has an Earnings ESP of +8.77% and a Zacks Rank #3.
Canopy Growth Corporation (CGC - Free Report) has an Earnings ESP of +24.56% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
What's in Store for Genesis Healthcare (GEN) This Season?
Genesis Healthcare, Inc. (GEN - Free Report) is scheduled to report second-quarter 2019 results on Aug 8.
The Zacks Consensus Estimate is pegged at a loss of 13 cents, which indicates 23.53% improvement from the year-ago reported figure. The consensus mark for revenues stands at $1.15 billion, implying a decline of 9.77% from the year-ago quarter’s reported figure.
Factors to Affect Q2 Results
We expect strong same-store EBITDAR growth driven by a more stable census and reimbursement environment, effective cost management, improvement in the company’s therapy and staffing businesses, and the impact of continued streamlining of its portfolio.
The company’s revenue growth will to some extent be offset by loss of revenues from divestitures, lower revenues in its rehab services business segments following the cancellation of low-margin therapy contracts.
The company’s expenses are likely to reduce due to decline in lease rental payments related to divestitures and closures. From 2018 through the first half of 2019, it made 65 divestitures. In the second quarter as well, it sold off 10 of its facilities.
As a result of improving operating trends and business portfolio optimization strategy, the company witnessed an increase in same-store occupancy levels in the first quarter and expects the same in the to-be-reported quarter.
We expect the company to deleverage its balance sheet with the funds received from numerous business sales made recently.
The company’s EBIDTA margins should also improve due to its focus on streamlining operations. In the last quarter, these reported margins were at their highest in two years, and the same should continue to improve in the coming quarters.
Earnings Surprise History
The company surpassed earnings estimates in three of the four reported quarters but the average remains a negative earnings surprise of 19.30%. This is depicted in the chart below:
Genesis Healthcare, Inc. Price and EPS Surprise
Genesis Healthcare, Inc. price-eps-surprise | Genesis Healthcare, Inc. Quote
What Our Model Says
Our proven model does not conclusively show that Genesis Healthcare is likely to beat earnings estimates this season because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to do so. But that is not the case here.
Earnings ESP: Genesis Healthcare has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter
Zacks Rank: Genesis Healthcare carries a Zacks Rank #3, which combined with Earnings ESP of 0.00% leaves our surprise prediction inconclusive.
Stocks That Warrant a Look
Here are some companies that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
CACI International, Inc. (CACI - Free Report) has an Earnings ESP of +4.02% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here
TOL Brothers, Inc. (TOL - Free Report) has an Earnings ESP of +8.77% and a Zacks Rank #3.
Canopy Growth Corporation (CGC - Free Report) has an Earnings ESP of +24.56% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>